Drug development is often constrained by development timelines that can extend 10–15 years from discovery to clinical implementation. While these timelines are intended to ensure safety and rigor, they frequently conflict with the urgency faced by patients with life-threatening diseases. A first-principles approach to translational medicine challenges the assumption that current development systems are inevitable and instead reexamines how such systems might be designed if built from fundamental biological, economic, and clinical realities. By deconstructing traditional development models into their basic components, opportunities emerge to redesign the translational ecosystem around speed of learning, integrated capabilities, and alignment with patient need. This perspective explores how integrated research environments, proximity between clinicians and scientists, and intelligent engagement with global regulatory frameworks can accelerate the translation of scientific insight into clinical impact. Ultimately, rethinking the architecture of translational medicine may be as important as advances in biology itself in determining how quickly new therapies reach patients.
Marleau et al. (Fri,) studied this question.